



TOS 2018 Review Course for the ABOM Exam Continuing Medical Education Information for Learners

Accreditation and Credit for Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) by The Obesity Society.

The Obesity Society is accredited by the ACCME to provide continuing medical education for physicians. The Obesity Society designates this live activity for a maximum of 18 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

1. Use evidence-based diagnostic/assessment tools to determine which treatment is most appropriate for specific patient types.
2. Develop appropriate behavioral, pharmacological and bariatric surgical approaches for the treatment of patients with obesity.
3. Apply the options that are currently available to develop strategies to treat patients with obesity including dietary strategies, physical activity interventions, medications and surgical options.
4. Implement evidence-based approaches for the treatment of obesity and be able to explain them in terms easily understood by the patient.
5. Incorporate evidence-based factors that predispose patients to weight gain—including genetic factors, relevant neuropeptides, alterations in energy expenditure and environmental factors—into appropriate patient-treatment strategies.
6. To acquire strategies that foster translation of predispositions into appropriate clinical treatment for patients with obesity.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. The Obesity Society has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. TOS requires additional disclosures beyond the ACCME definition of a commercial interest, as indicated by an asterisk in the list below. These include food, weight loss, and supplement industry disclosures. In the list below, the nature of the relationship and company are followed by the industry of that company.

Speaker Disclosures:

Name	Review Course 2018 Disclosure
Bays, Harold (MD, FTOS, FOMA, FACC, FACE, FNLA)	Contracted Research relationship with AstraZeneca; Pharmaceuticals; Contracted Research relationship with Boehringer Ingelheim; Pharmaceuticals; Contracted Research relationship with Eisai; Pharmaceuticals; Contracted Research relationship with Janssen; Pharmaceuticals; Contracted Research relationship with Johnson and Johnson; Pharmaceuticals; Contracted Research relationship with Merck; Pharmaceuticals; Contracted Research relationship with Novartis; Pharmaceuticals; Contracted Research relationship with NovoNordisk; Pharmaceuticals; Consulting Fee relationship with Eisai; Pharmaceuticals; Consulting Fee relationship with Janssen; Pharmaceuticals; Consulting Fee relationship with Johnson and Johnson; Pharmaceuticals; Consulting Fee relationship with Merck; Pharmaceuticals; Consulting Fee relationship with Novartis; Pharmaceuticals; Speakers Bureau relationship with Orexigen; Pharmaceuticals
Collazo-Clavell, Maria (MD)	No Relevant Financial Relationships
Donahoo, William (MD)	No Relevant Financial Relationships
Jakicic, John (PhD, FTOS)	Consulting Fee relationship with Weight Watchers International, Inc.; Weight Management*
Jensen, Michael (MD)	Fee went to Mayo Clinic relationship with Novo Nordisk; Pharmaceuticals; Stock relationship with Novartis; Pharmaceuticals; Stock relationship with Procter & Gamble; Pharmaceuticals

O'Neil, Patrick (PhD)	Contracted Research relationship with NovoNordisk; Pharmaceuticals; Honorarium for non-promotional talks relationship with NovoNordisk; Pharmaceuticals; Honorarium for non-promotional talks relationship with Robard Corporation; Weight Management*
Skelton, Joseph (MD, MS)	No Relevant Financial Relationships
Tsai, Adam (MD, MSCE, FACP)	No Relevant Financial Relationships
Wolfe, Bruce (MD, FACS, FASMBS)	No Relevant Financial Relationships

* Denotes TOS-required disclosures of relationships with food, supplement, or weight loss companies.

Planner Disclosures: TOS Education Committee (Review Course) disclosures:

Name	ROLE	OW2018 Disclosure
Angelopoulos, Theodore (PhD)	Committee Member	No Relevant Financial Relationships
Collazo-Clavell, Maria (MD)	Committee Member	No Relevant Financial Relationships
Davidson, Lance (PhD)	Committee Member	No Relevant Financial Relationships
Hong, Kurt (MD)	Committee Member	No Relevant Financial Relationships
Igel, Leon	Committee Member	No Relevant Financial Relationships
Mandell, Lynda (MD, PhD)	Committee Member	No Relevant Financial Relationships
McClurkan, Michael (MD)	Committee Member	Speakers Bureau relationship with NovoNordisk Speaker Bureau; Pharmaceuticals
O'Connor, Teresia (MD)	Committee Member	No Relevant Financial Relationships
Peterson, Ninoska (PhD)	Committee Member	No Relevant Financial Relationships
Purnell, Jonathan (MD, FTOS)	Committee Member	Consulting Fee relationship with Novo Nordisk; Pharmaceuticals
Schwartz, Gary (PhD)	Council Liaison	No Relevant Financial Relationships
Shah, Nihar (MD)	Committee Member	No Relevant Financial Relationships
Tsai, Adam (MD, MSCE, FACP)	Chair	No Relevant Financial Relationships

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee. One committee member did step down upon developing a potential conflict.

CME Oversight Committee Names (Reviewers)	ROLE	Disclosures
Herring, Sharon (MD, MPH)	Former Committee Member	Stepped down Feb 2018 after accepting a contracted research role with pharmaceutical company Novo Nordisk. Prior to that date, had no relevant financial relationships.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated November 6, 2018.